Patent · US Active

Medical use of a DPP-4 inhibitor

US9526728B2 · kind B2 · utility

0Cited by

143References

8Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Thomas KLEIN · Radolfzell, DE
Andrew Advani · Toronto, CA
Kim Alexander Connelly · Toronto, CA
Richard Ernest Gilbert · Toronto, CA

Key dates

Filing date	Feb 27, 2015
Grant date	Dec 27, 2016
Priority date	—
Expiry date	Feb 27, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for use in a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.